Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

SSilexion Therapeutics Corp

EconomyAI buildoutMarket MapFundsWatchlist
Log in
S

Silexion Therapeutics Corp

$0.39Close · Sep 22, 2026
  • Overview
  • Financial statements
  • Metrics
    • Revenue & profit
    • Revenue by segment
    • Launches
    • Revenue concentration
    • Margins
    • Contracted revenue
    • Off-balance-sheet commitments
    • Cash flow
    • Cash & debt
    • Earnings per share
    • P/E ratio
    • Share count & dilution
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • Insider Transactions
Loading financial graphs

Metrics

Revenue & profit
Revenue by segment
Margins
Contracted revenue
Cash flow
Cash & debt
Earnings per share
Share count & dilution

Metrics

Compare cash generated by the business, spending on long-lived assets, and what remains afterward.Formula: Free cash flow = operating cash flow − capital expenditures
$
2025202320242025-10M-8M-6M-4M-2M0
    • Capex: purchases of property, plant and equipment
    • Capex: purchases of property, plant and equipment
    • Capex: purchases of property, plant and equipment
    Latest period 2025. Operating cash flow -10.8M. Capex -9K. Free cash flow -10.8M.
    Operating cash flowCapexFree cash flow
    Compare the company’s cash cushion with its borrowings. Negative net cash means debt is greater than cash.Formula: Net cash = cash − debt
    2026202320242025202602M4M6M8M
        Latest period 2026. Cash 2.2M.
        CashDebtNet cash
        Profit for each share over the trailing 12 months, adjusted for stock splits.Formula: Earnings available to common shareholders ÷ weighted-average shares
        $/shareUsing split history cached 2026-09-23; assuming no new splits
        20252023202420250.00100.00200.00300.00
          • Earnings period 2023-01-01 to 2023-12-31. Shares as of 2023-12-31: 97,120,000 source shares.
          • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 123,290,000 source shares.
          • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 312,665 source shares.
          Latest period FY 2025. EPS (TTM) 380.98.
          EPS (TTM)
          How much investors pay for each dollar of the company’s yearly earnings. It is not useful when the company has no profit.Formula: Share price ÷ trailing 12-month EPS
          Using split history cached 2026-09-23; assuming no new splits
          20252023202420250x500x1,000x1,500x
            • Earnings period 2023-01-01 to 2023-12-31. Shares as of 2023-12-31: 97,120,000 source shares. Nearby weekly price on 2024-01-02.
            • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 123,290,000 source shares. Nearby weekly price on 2025-01-03.
            • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 312,665 source shares. Nearby weekly price on 2026-01-02.
            Latest period FY 2025. P/E ratio 0x.
            P/E ratio
            See how the number of shares changes over time. More shares can mean each existing share owns a smaller slice of the company.Formula: Outstanding shares = issued shares − treasury shares Share-count growth = (current shares ÷ previous shares − 1) × 100%
            Stock split history may be out of date.
            20262023202420252026020M40M60M80M100M120M
            2025-07-29: Reverse stock split 1-for-15
            2026-05-29: Reverse stock split 1-for-10
                Latest period 2026. Shares outstanding 1.2M. Class detail unavailable 1.2M.
                Class detail unavailableStock split